Interview: Chen Qiyu – Chairman, Fosun Pharma, China
Chen Qiyu, chairman of Fosun Pharma, discusses how the company is helping China achieve its ‘Healthy China 2020’ goals as well as its unique business model and company culture. Fosun…
Address: Fosun Commercial Building No. 2 Fuxing Road (East) Shanghai,
Zip Code:200010
,China
Tel: -23137935
Web: http://www.fosunpharma.com/
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”, stock code: 600196), was established in 1994 and listed on Shanghai Stock Exchange in August 1998. Now it has turned a leading listed company in Chinese pharmaceutical industry.
Fosun Pharma’s net profits have increased by 13.55 times since its 13-year listed and its annual compound growth rate has reached 24.26%. Meanwhile, its net assets and net profits are in front rank of the listed companies in Chinese pharmaceutical industry.
Fosun Pharma specializing in modern biological medical & health industry, has taken great opportunities of the rapid growth of China’s medical market and Chinese enterprises’ access to the world’s predominant medical market, and accelerated industry integration and implemented key product strategy by following the business principle of “Brand, Innovation, High-efficiency and Globalization” so as to realize stable operation and rapid development, at the same time, it has become a large pharmaceutical group on the aspect of R&D, innovation, marketing, merging & integration and team building by regarding R&D, manufacturing and distribution of the medicines as the core and taking the lead of the scale and market role in diagnostic medicines and medical instruments.
Vertically integrated pharmaceutical company
Chen Qiyu, chairman of Fosun Pharma, discusses how the company is helping China achieve its ‘Healthy China 2020’ goals as well as its unique business model and company culture. Fosun…
Ingrid Zhang, president of Novartis Pharmaceuticals China, shares the transformation of Novartis China in the past two years in line with the global Novartis vision; their aspiration to become a…
Robert Braithwaite, CEO and co-founder at LUQA Pharmaceuticals, a China-based specialty pharmaceutical company focusing on dermatology and aesthetics, shares his inspiration for establishing the company in 2010 to bring ‘hidden…
TJ Deng, GM China and BioDuro Discovery; and Ian Wisenberg, CFO of BioDuro, share the strategic rationale behind Advent International’s 2019 investment into the company; the focus of BioDuro 4.0…
Dr Chengbin Wu, founder and CEO of EpimAb Biotherapeutics, introduces their exciting and proprietary bispecific antibody-generating platform, Fabs-In-Tandem Immunoglobulin (FIT-Ig®) and its ability to discover and generate novel and differentiated…
Amidst the sea of Big Pharma executives jumping ship to start highly regarded and attention-grabbing biotech companies, bolstered by the huge influx of capital, the opening of stock exchanges in…
William Wei Cao, chairman and CEO of Gracell, shares the fascinating journey that inspired him to establish Gracell in Shanghai to tackle the four big challenges facing the global CAR-T…
Olivier Dessajan, China director of Groupe Colisee, the fourth-largest European provider of elderly care facilities and solutions, shares the group’s expansion into China with two medical nursing homes in Guangzhou…
Julio Gay-Ger, an industry and Eli Lilly veteran, shares how he is leveraging on his 23 years of experience managing Lilly affiliates in LATAM to deliver on Lilly’s objective to…
Yan Hao, chairman and CEO of EPS Group shares the company’s journey to become Japan’s largest and most comprehensive provider of optimal outsourced solutions to the healthcare industry through its…
Asgar Rangoonwala, president of Xian Janssen, Janssen’s Chinese affiliate, shares the key milestones for the affiliate in the past two years, how Janssen is investing in bringing new innovations to…
Dr Jun Bao, appointed president and CEO of Impact Therapeutics in October 2018, shares his aspirations for Impact to be a leader in synthetic lethality in oncology; the importance of…
Click here to register and download PharmaBoardroom’s latest report: Healthcare & Life Sciences Review: China. From the world’s ninth largest pharma market in 2007 to its second-biggest merely 12…
See our Cookie Privacy Policy Here